Type 2 Diabetes

Literature is scarce in identifying and characterizing risk of post-operative diabetes mellitus among patients with pancreatic cystic lesions.

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

In the last of our 3-part series examining the idea of a cardiometabolic subspecialty, Simon Murray, MD, offers his thoughts on who should be treating patients with type 2 diabetes.

More studies are planned testing the impact of finerenone.

An endocrinologist from Brigham and Women’s Hospital discusses the latest in diabetes management.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

About 20% of 81 positive patients experienced critical neurological complications; further, half had a pre-existing history of high blood pressure or type 2 diabetes.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The indication comes from collaborative work among experts and community leaders coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.

Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.

George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.

A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

Pooled analysis of SUSTAIN 6 and PIONEER 6 trials indicates the impact of semaglutide impact on MACE was present regardless of baseline triglyceride levels among diabetic patients.

Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

In honor of World Diabetes Day, we reached out to Lucia Novak, CRNP, to get her perspective on the role of nurses in the diabetes care model as "The Nurse and Diabetes" has been chosen as the official theme of this year's World Diabetes Day.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

A practicing endocrinologist offers her thoughts on a recent change by the AACE from the American Association of Clinical Endocrinologists to the American Association of Clinical Endocrinology.